Literature DB >> 3057964

Attenuation of acute lung injury in septic guinea pigs by pentoxifylline.

A Ishizaka1, Z H Wu, K E Stephens, H Harada, R S Hogue, P T O'Hanley, T A Raffin.   

Abstract

Pentoxifylline (PTXF), a drug demonstrated to improve intermittent claudication, is a methylxanthine that increases intracellular cyclic AMP (cAMP) and, unlike theophylline, has few side effects. Because increased cAMP levels have been associated with a decrease in lung injury, we examined the effects of PTXF on acute lung injury in a septic guinea pig model. Five groups of guinea pigs were studied over a period of 8 h. (Group I: saline control injected intravenously with 2 ml of saline; Group II: septic control injected intravenously with 2 x 10(9) Escherichia coli; Group III: E. coli septicemia plus PTXF bolus 20 mg/kg injected 5 min before E. coli injection; Group IV: E. coli septicemia plus PTXF continuous infusion, begun with bolus [20 mg/kg] followed by continuous infusion [20 mg/kg/h] started 60 min before injection of E. coli; Group V: PTXF continuous infusion [20 mg/kg/h] control). Arterial blood gases, arterial blood pressure, and blood WBC counts were monitored serially for 8 h. Lung water (wet-to-dry ratio), the concentration ratio of 125I-labeled albumin in bronchoalveolar lavage (BAL) fluid to that in plasma (albumin index; AI), total cell count in BAL fluid, thiobarbituric-acid-reactive material (TBARM), and the lysosomal enzyme beta-glucuronidase (beta-G) were examined. Lung tissue was studied histologically to assess neutrophil accumulation. Our results showed that E. coli septicemia caused significant peripheral neutropenia and histopathologic evidence of neutrophil alveolitis associated with an increased ratio of TBARM and beta-G in BAL fluid as compared with those in plasma (TBARM BAL ratio and beta-G BAL ratio).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3057964     DOI: 10.1164/ajrccm/138.2.376

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  12 in total

1.  Cellular mechanisms of acute lung injury: implications for future treatment in the adult respiratory distress syndrome.

Authors:  S C Donnelly; C Haslett
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

Review 2.  Intensive care.

Authors:  S Sinclair; M Singer
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

3.  Pentoxifylline modulation of plasma membrane functions in human polymorphonuclear leukocytes.

Authors:  W L Hand; M L Butera; N L King-Thompson; D L Hand
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

4.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.

Authors:  S Endres; H J Fülle; B Sinha; D Stoll; C A Dinarello; R Gerzer; P C Weber
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

5.  Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis.

Authors:  X Sáez-Llorens; O Ramilo; M M Mustafa; J Mertsola; C de Alba; E Hansen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Pentoxifylline attenuates acute lung injury induced by microemboli.

Authors:  C Y Shen; K Hsu; D Wang; H C Yan
Journal:  Experientia       Date:  1995-09-29

7.  Effects of pentoxifylline on equine neutrophil function and flow properties.

Authors:  D J Weiss; R J Geor; S M Burris; C M Smith
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

Review 8.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 9.  Cystic fibrosis. 2. Lung injury in cystic fibrosis.

Authors:  J S Elborn; D J Shale
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

10.  Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity.

Authors:  J Semmler; U Gebert; T Eisenhut; J Moeller; M M Schönharting; A Alléra; S Endres
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.